文章：

肝细胞癌的异质性：从机制到临床意义

Heterogeneity of hepatocellular carcinoma: from mechanisms to clinical implications

原文发布日期：2024-03-18 

英文摘要：

Hepatocellular Carcinoma (HCC) is one of the most common types of primary liver cancer. Current treatment options have limited efficacy against this malignancy, primarily owing to difficulties in early detection and the inherent resistance to existing drugs. Tumor heterogeneity is a pivotal factor contributing significantly to treatment resistance and recurrent manifestations of HCC. Intratumoral heterogeneity is an important aspect of the spectrum of complex tumor heterogeneity and contributes to late diagnosis and treatment failure. Therefore, it is crucial to thoroughly understand the molecular mechanisms of how tumor heterogeneity develops. This review aims to summarize the possible molecular dimensions of tumor heterogeneity with an emphasis on intratumoral heterogeneity, evaluate its profound impact on the diagnosis and therapeutic strategies for HCC, and explore the suitability of appropriate pre-clinical models that can be used to best study tumor heterogeneity; thus, opening new avenues for cancer treatment. 

摘要翻译： 

肝细胞癌（HCC）是最常见的原发性肝癌类型之一。当前治疗方案对这种恶性肿瘤的疗效有限，主要源于早期检测的困难性以及对现有药物的固有耐药性。肿瘤异质性是导致治疗耐药和HCC复发的重要因素。瘤内异质性作为复杂肿瘤异质性谱系的重要方面，直接导致延迟诊断和治疗失败。因此，深入理解肿瘤异质性形成的分子机制至关重要。本综述旨在从分子维度总结肿瘤异质性（重点关注瘤内异质性）的可能机制，评估其对HCC诊断和治疗策略的深远影响，并探讨可用于研究肿瘤异质性的临床前模型的适用性，从而为癌症治疗开辟新途径。

原文链接：

Heterogeneity of hepatocellular carcinoma: from mechanisms to clinical implications